|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
12,750,000 |
Market
Cap: |
180.67(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$7.77 - $20.32 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Co.'s product candidates include GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers; and granulocyte macrophage colony-stimulating factor immunoadjuvant, which is to improve monocyte and neutrophil cytotoxicity against melanoma tumor cells and to improve activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
11,800 |
193,625 |
276,825 |
324,675 |
Total Buy Value |
$166,175 |
$2,799,883 |
$3,733,147 |
$4,328,600 |
Total People Bought |
2 |
2 |
2 |
2 |
Total Buy Transactions |
6 |
10 |
24 |
57 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-20 |
2024-03-19 |
2023-09-19 |
2022-09-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Thompson Jaye |
VP Clinical Reg Affairs |
|
2024-08-12 |
4 |
B |
$13.85 |
$11,080 |
D/D |
800 |
263,148 |
2.74 |
6% |
|
Patel Snehal |
CEO and CFO |
|
2024-08-06 |
4 |
B |
$13.81 |
$27,620 |
D/D |
2,000 |
5,534,602 |
3.23 |
-0% |
|
Patel Snehal |
CEO and CFO |
|
2024-08-05 |
4 |
B |
$13.18 |
$72,490 |
D/D |
5,500 |
5,532,602 |
3.23 |
7% |
|
Thompson Jaye |
VP Clinical Reg Affairs |
|
2024-08-02 |
4 |
B |
$15.15 |
$15,150 |
D/D |
1,000 |
262,348 |
2.74 |
-1% |
|
Patel Snehal |
CEO and CFO |
|
2024-07-23 |
4 |
B |
$15.89 |
$23,835 |
D/D |
1,500 |
5,527,102 |
3.15 |
-12% |
|
Thompson Jaye |
VP Clinical Reg Affairs |
|
2024-07-18 |
4 |
B |
$16.00 |
$16,000 |
D/D |
1,000 |
261,348 |
2.74 |
-9% |
|
Patel Snehal |
CEO and CFO |
|
2024-06-13 |
4 |
B |
$14.30 |
$2,499,998 |
D/D |
174,825 |
5,525,602 |
3.23 |
-5% |
|
Patel Snehal |
CEO and CFO |
|
2024-04-01 |
4 |
B |
$19.08 |
$57,240 |
D/D |
3,000 |
5,350,777 |
3.23 |
-30% |
|
Patel Snehal |
CEO and CFO |
|
2024-03-22 |
4 |
B |
$19.98 |
$49,950 |
D/D |
2,500 |
5,347,777 |
3.23 |
-27% |
|
Patel Snehal |
CEO and CFO |
|
2024-03-20 |
4 |
B |
$17.68 |
$26,520 |
D/D |
1,500 |
5,345,277 |
3.23 |
-12% |
|
Patel Snehal |
CEO and CFO |
|
2024-03-05 |
4/A |
B |
$12.49 |
$43,715 |
D/D |
3,500 |
5,343,777 |
3.23 |
- |
|
Patel Snehal |
CEO and CFO |
|
2024-03-05 |
4 |
B |
$12.49 |
$380,945 |
D/D |
30,500 |
5,343,777 |
3.23 |
26% |
|
Patel Snehal |
CEO and CFO |
|
2024-03-04 |
4 |
B |
$13.03 |
$53,423 |
D/D |
4,100 |
5,340,277 |
3.23 |
21% |
|
Patel Snehal |
CEO and CFO |
|
2024-02-16 |
4 |
B |
$11.16 |
$120,528 |
D/D |
10,800 |
5,336,177 |
3.23 |
54% |
|
Patel Snehal |
CEO and CFO |
|
2024-02-15 |
4 |
B |
$11.07 |
$140,589 |
D/D |
12,700 |
5,325,377 |
3.23 |
46% |
|
Patel Snehal |
CEO and CFO |
|
2023-11-10 |
4 |
B |
$10.17 |
$50,838 |
D/D |
5,000 |
5,312,677 |
3.23 |
93% |
|
Patel Snehal |
CEO and CFO |
|
2023-11-03 |
4 |
B |
$9.11 |
$31,885 |
D/D |
3,500 |
5,307,677 |
3.23 |
93% |
|
Thompson Jaye |
VP Clinical Reg Affairs |
|
2023-10-27 |
4 |
B |
$8.57 |
$4,285 |
D/D |
500 |
260,348 |
2.66 |
80% |
|
Patel Snehal |
CEO and CFO |
|
2023-10-26 |
4 |
B |
$7.97 |
$19,925 |
D/D |
2,500 |
5,304,177 |
3.15 |
99% |
|
Patel Snehal |
CEO and CFO |
|
2023-10-25 |
4 |
B |
$7.91 |
$19,775 |
D/D |
2,500 |
5,301,677 |
3.15 |
73% |
|
Patel Snehal |
CEO and CFO |
|
2023-10-10 |
4 |
B |
$9.07 |
$9,070 |
D/D |
1,000 |
5,299,177 |
3.15 |
39% |
|
Patel Snehal |
CEO and CFO |
|
2023-10-04 |
4 |
B |
$8.63 |
$17,260 |
D/D |
2,000 |
5,298,177 |
3.15 |
-2% |
|
Thompson Jaye |
VP Clinical Reg Affairs |
|
2023-09-26 |
4 |
B |
$8.71 |
$5,226 |
D/D |
600 |
259,848 |
2.74 |
4% |
|
Patel Snehal |
CEO and CFO |
|
2023-09-19 |
4 |
B |
$8.95 |
$35,800 |
D/D |
4,000 |
5,296,177 |
3.23 |
3% |
|
Patel Snehal |
CEO and CFO |
|
2023-09-11 |
4 |
B |
$9.48 |
$9,480 |
D/D |
1,000 |
5,292,177 |
3.15 |
-4% |
|
113 Records found
|
|
Page 1 of 5 |
|
|